Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MK-663: Phase IIb data; Phase III

In a 617-patient six week dose-ranging study, patients given any dose of

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE